Literature DB >> 22748950

Review of vasopressin use in gynecologic surgery.

Scott Chudnoff1, Sivan Glazer, Mark Levie.   

Abstract

Vasopressin has been used in gynecologic surgery since the 1950s. Since its initial introduction, multiple applications of vasopressin have been explored. The expansion of vasopressin usage in gynecologic surgery is being fueled in part by the increase in minimally invasive surgical techniques, in which alternative methods of temporary hemostasis are in high demand. Nevertheless, much criticism has been directed toward use of vasopressin because of reports of serious complications including cardiac arrest. These concerns have caused several countries to restrict or prohibit the use of this valuable drug. This review explores the mechanisms of vasopressin, the current literature on vasopressin use in gynecologic surgery, and evaluates the reported complications associated with vasopressin use.
Copyright © 2012 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748950     DOI: 10.1016/j.jmig.2012.03.022

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  3 in total

1.  The HYSTER study: the effect of intracervically administered terlipressin versus placebo on the number of gaseous emboli and fluid intravasation during hysteroscopic surgery: study protocol for a randomized controlled clinical trial.

Authors:  Lucilla E Overdijk; Bart M P Rademaker; Paul J M van Kesteren; Peter de Haan; Robert K Riezebos; Oscar C H Haude
Journal:  Trials       Date:  2018-02-14       Impact factor: 2.279

2.  Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants.

Authors:  R Fusun Sirkeci; Anna Maria Belli; Isaac T Manyonda
Journal:  Gynecol Surg       Date:  2017-07-06

3.  Hemodynamic changes following accidental infiltration of a high dose of vasopressin.

Authors:  Jae Won Kim; Goo Kim; Tae Woo Kim; Woong Han; Mo Se Kim; Chang Young Jeong; Dong Ho Park
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.